Neuroendocrine neoplasms
Conditions
Brief summary
Progression free survival (PFS).
Detailed description
Overall survival (OS), The proportion of patients who are considered eligible for peptide receptor radionuclide therapy based on their 64Cu-DOTATATE PET/CT scan, The correlation between standardized uptake values from tumors and healthy tissues derived from manually depicted regions-of-interests measured on 18FDG and 64Cu-DOTATATE
Interventions
Sponsors
Rigshospitalet
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS), The proportion of patients who are considered eligible for peptide receptor radionuclide therapy based on their 64Cu-DOTATATE PET/CT scan, The correlation between standardized uptake values from tumors and healthy tissues derived from manually depicted regions-of-interests measured on 18FDG and 64Cu-DOTATATE | — |
Countries
Denmark
Outcome results
None listed